Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor

Hugo R. Arias, Nikolai B. Fedorov, Lisa C. Benson, Patrick M. Lippiello, Greg J. Gatto, Dominik Feuerbach, Marcelo O. Ortells

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The interaction of the selective norepinephrine reuptake inhibitor (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor (nAChR) in different conformational states was studied by several functional and structural approaches. Patch-clamp and Ca2+-influx results indicate that (-)-reboxetine does not activate hα4β2 nAChRs via interaction with the orthosteric sites, but inhibits agonist-induced hα4β2 activation by a noncompetitive mechanism. Consistently, the results from the electrophysiologybased functional approach suggest that (-)-reboxetine may act via open channel block; therefore, it is capable of producing a usedependent type of inhibition of the hα4β2 nAChR function. We tested whether (-)-reboxetine binds to the luminal [3H]imipramine site. The results indicate that, although (-)-reboxetine binds with low affinity to this site, it discriminates between the resting and desensitized hα4β2 nAChR ion channels. Patch-clamp results also indicate that (-)-reboxetine progressively inhibits the hα4β2 nAChR with two-fold higher potency at the end of one-second application of agonist, compared with the peak current. The molecular docking studies show that (-)-reboxetine blocks the ion channel at the level of the imipramine locus, between M2 rings 6′ and 14′. In addition, we found a (-)-reboxetine conformer that docks in the helix bundle of the α4 subunit, near the middle region. According to molecular dynamics simulations, (-)-reboxetine binding is stable for both sites, albeit less stable than imipramine. The interaction of these drugs with the helix bundle might alter allostericaly the functionality of the channel. In conclusion, the clinical action of (-)-reboxetine may be produced (at least partially) by its inhibitory action on hα4β2 nAChRs.

Original languageEnglish
Pages (from-to)113-123
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume344
Issue number1
DOIs
StatePublished - 1 Jan 2013
Externally publishedYes

Fingerprint

Nicotinic Receptors
Imipramine
Ion Channels
reboxetine
Molecular Dynamics Simulation
Drug Interactions
Norepinephrine

Cite this

Arias, Hugo R. ; Fedorov, Nikolai B. ; Benson, Lisa C. ; Lippiello, Patrick M. ; Gatto, Greg J. ; Feuerbach, Dominik ; Ortells, Marcelo O. / Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor. In: Journal of Pharmacology and Experimental Therapeutics. 2013 ; Vol. 344, No. 1. pp. 113-123.
@article{85d9481afc6b48589de129699f6da3bd,
title = "Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor",
abstract = "The interaction of the selective norepinephrine reuptake inhibitor (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor (nAChR) in different conformational states was studied by several functional and structural approaches. Patch-clamp and Ca2+-influx results indicate that (-)-reboxetine does not activate hα4β2 nAChRs via interaction with the orthosteric sites, but inhibits agonist-induced hα4β2 activation by a noncompetitive mechanism. Consistently, the results from the electrophysiologybased functional approach suggest that (-)-reboxetine may act via open channel block; therefore, it is capable of producing a usedependent type of inhibition of the hα4β2 nAChR function. We tested whether (-)-reboxetine binds to the luminal [3H]imipramine site. The results indicate that, although (-)-reboxetine binds with low affinity to this site, it discriminates between the resting and desensitized hα4β2 nAChR ion channels. Patch-clamp results also indicate that (-)-reboxetine progressively inhibits the hα4β2 nAChR with two-fold higher potency at the end of one-second application of agonist, compared with the peak current. The molecular docking studies show that (-)-reboxetine blocks the ion channel at the level of the imipramine locus, between M2 rings 6′ and 14′. In addition, we found a (-)-reboxetine conformer that docks in the helix bundle of the α4 subunit, near the middle region. According to molecular dynamics simulations, (-)-reboxetine binding is stable for both sites, albeit less stable than imipramine. The interaction of these drugs with the helix bundle might alter allostericaly the functionality of the channel. In conclusion, the clinical action of (-)-reboxetine may be produced (at least partially) by its inhibitory action on hα4β2 nAChRs.",
author = "Arias, {Hugo R.} and Fedorov, {Nikolai B.} and Benson, {Lisa C.} and Lippiello, {Patrick M.} and Gatto, {Greg J.} and Dominik Feuerbach and Ortells, {Marcelo O.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1124/jpet.112.197905",
language = "English",
volume = "344",
pages = "113--123",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor. / Arias, Hugo R.; Fedorov, Nikolai B.; Benson, Lisa C.; Lippiello, Patrick M.; Gatto, Greg J.; Feuerbach, Dominik; Ortells, Marcelo O.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 344, No. 1, 01.01.2013, p. 113-123.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor

AU - Arias, Hugo R.

AU - Fedorov, Nikolai B.

AU - Benson, Lisa C.

AU - Lippiello, Patrick M.

AU - Gatto, Greg J.

AU - Feuerbach, Dominik

AU - Ortells, Marcelo O.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The interaction of the selective norepinephrine reuptake inhibitor (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor (nAChR) in different conformational states was studied by several functional and structural approaches. Patch-clamp and Ca2+-influx results indicate that (-)-reboxetine does not activate hα4β2 nAChRs via interaction with the orthosteric sites, but inhibits agonist-induced hα4β2 activation by a noncompetitive mechanism. Consistently, the results from the electrophysiologybased functional approach suggest that (-)-reboxetine may act via open channel block; therefore, it is capable of producing a usedependent type of inhibition of the hα4β2 nAChR function. We tested whether (-)-reboxetine binds to the luminal [3H]imipramine site. The results indicate that, although (-)-reboxetine binds with low affinity to this site, it discriminates between the resting and desensitized hα4β2 nAChR ion channels. Patch-clamp results also indicate that (-)-reboxetine progressively inhibits the hα4β2 nAChR with two-fold higher potency at the end of one-second application of agonist, compared with the peak current. The molecular docking studies show that (-)-reboxetine blocks the ion channel at the level of the imipramine locus, between M2 rings 6′ and 14′. In addition, we found a (-)-reboxetine conformer that docks in the helix bundle of the α4 subunit, near the middle region. According to molecular dynamics simulations, (-)-reboxetine binding is stable for both sites, albeit less stable than imipramine. The interaction of these drugs with the helix bundle might alter allostericaly the functionality of the channel. In conclusion, the clinical action of (-)-reboxetine may be produced (at least partially) by its inhibitory action on hα4β2 nAChRs.

AB - The interaction of the selective norepinephrine reuptake inhibitor (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor (nAChR) in different conformational states was studied by several functional and structural approaches. Patch-clamp and Ca2+-influx results indicate that (-)-reboxetine does not activate hα4β2 nAChRs via interaction with the orthosteric sites, but inhibits agonist-induced hα4β2 activation by a noncompetitive mechanism. Consistently, the results from the electrophysiologybased functional approach suggest that (-)-reboxetine may act via open channel block; therefore, it is capable of producing a usedependent type of inhibition of the hα4β2 nAChR function. We tested whether (-)-reboxetine binds to the luminal [3H]imipramine site. The results indicate that, although (-)-reboxetine binds with low affinity to this site, it discriminates between the resting and desensitized hα4β2 nAChR ion channels. Patch-clamp results also indicate that (-)-reboxetine progressively inhibits the hα4β2 nAChR with two-fold higher potency at the end of one-second application of agonist, compared with the peak current. The molecular docking studies show that (-)-reboxetine blocks the ion channel at the level of the imipramine locus, between M2 rings 6′ and 14′. In addition, we found a (-)-reboxetine conformer that docks in the helix bundle of the α4 subunit, near the middle region. According to molecular dynamics simulations, (-)-reboxetine binding is stable for both sites, albeit less stable than imipramine. The interaction of these drugs with the helix bundle might alter allostericaly the functionality of the channel. In conclusion, the clinical action of (-)-reboxetine may be produced (at least partially) by its inhibitory action on hα4β2 nAChRs.

UR - http://www.scopus.com/inward/record.url?scp=84871684745&partnerID=8YFLogxK

U2 - 10.1124/jpet.112.197905

DO - 10.1124/jpet.112.197905

M3 - Article

C2 - 23010362

AN - SCOPUS:84871684745

VL - 344

SP - 113

EP - 123

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -